Fully taxed op earnings should be around 80c for the year on a pro-forma basis. Much better op cash flow since they don't pay tax. After that its all about sales growth. Onclogy looks good with 10% sequential growth - that was the key thing to watch with an aquisition.
Analysts seem to either love or hate this stock, so the average is demanding a lot for what is a WIP.
Margins good and 2H sales guidance strong. Lots of cash. Should be higher pps...
They confuse the investor by mixing calender and FY08, but it seems that they expect to close the Oncobionics aq by end of 08 F, ie mid next year. That would be a pretty sure sign that the technology works, if it does. And if it does it vastly increases the value of ANGO stock.
Without IRE, we are looking at sales up 20% and eps up 30% in FY09... say analyst averages... for GAAP earnings.
Assuming legal costs go away and are 1offs next year would be 80c, this quarter was 14c.